Trial Profile
Evaluation of tumor response to combination therapy of Nivolumab and Ipilumab verusus monotherapy of either Nivolumab or Pembrolizumab in melanoma patients by analyzing T cell exhaustion marker as predictor of response
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jul 2016
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Biomarker; Pharmacodynamics
- 22 Jul 2016 New trial record
- 07 Jun 2016 Results (n=53) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.